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 LISTA DE ABREVIATURAS 
 
Ct           Cycle threshold 
CTLA4   Cytotoxic T-Lymphocyte-Associated Protein 4  
DHPS     Deoxyhypusine synthase 
FAS        TNF receptor superfamily, member 6  
FDR        False discovery rate  
FIGO      International Federation of Gynecology and Obstetrics  
HLA        Human leukocyte antigens  
HPV        Papilomavírus Humano 
IC           Intervalo de confiança 
ICOS      Inducible T-cell co-stimulator 
IFNG      Interferon, gamma  
IL10        Interleucina 10  
IL6          Interleucina 6  
KIR         killer immunoglobulin-like receptor 
LD           Linkage disequilibrium; 
NIC         Neoplasia intra-epitelial da cervix 
OR          Odds ratio 
PAPD5    PAP associated domain containing 5 
PCR        Reação em cadeia da polimerase 
RFLP      Restriction fragment length polymorphism 
SSP        Sequence specific primer 
PDCD1   Programmed cell death 1  
RT-PCR  Real Time - PCR  
SNP         Polimorfismo em um único nucleotídeo 
TGFB1     Transforming growth factor beta1  
TNFA       Tumor necrosis factor alpha 
Treg         Células T regulatórias 
UR           Unidade relativa 
 
Xi 
 
 RESUMO 
Os objetivos de nosso trabalho foram: 1) investigar a relação entre 
polimorfismos dos genes CD28, ICOS, CTLA4, PDCD1, FAS, TGFB1, IFNG, IL6, 
IL10, TNFA e a ocorrência de carcinoma do colo uterino; 2) investigar a relação 
entre nível de expressão dos genes CD28, CTLA4, ICOS, ICOSL, CD80, CD86, 
GZMB (granzima B) em biópsias de carcinoma de colo uterino, no momento do 
diagnóstico, e a evolução do tumor após o tratamento. Materiais e Métodos: 1) A 
determinação dos polimorfismos foi realizada através dos métodos PCR-RFLP, 
para os SNPs: CD28 int3 (+17 T>C), CTLA4 promoter (-319 C>T), CTLA4 exon 1 
(+49 A>G), ICOS 3’UTR (+1564 T>C), PDCD1 exon 5 (+7785 C>T) e FAS 
promoter (-670 G>A) e PCR-SSP para TNFA promoter (-308 G>A), IL6 promoter 
(-174 G>C), IFNG int1 (+874 A>T), TGFB1 codon 10 (+869 T>C), codon 25  (+915 
G>C) and IL10 promoter (-1082 A>G), (-819 C>T), (-592 C>A) SNPs. Um 
algoritmo foi desenvolvido para identificar genótipos de SNPs isolados e/ou em 
combinações de 2 e 3 genótipos associados com a doença 2) Expressão gênica 
foi determinada, por PCR em tempo real, em biópsias de carcinoma cervical de 
pacientes posteriormente classificadas em dois grupos: 10 pacientes sem 
envidência do tumor (evolução clínica boa) após 6 meses do final do tratamento e 
8 pacientes nas quais o tumor foi detectado (evolução clínica ruim) neste período. 
Resultados: 1) Nenhuma associação significante foi observada com os SNPs 
analisados isoladamente. A análise do multi-locus revelou, em pacientes, maiores 
frequências de três combinações de três genótipos (CD28 +17 int3(TT)/IFNG+874 
int1(AA)/TNFA-308(GG), CD28+17 int3 (TT)/IFNG+874 Iint1(AA)/PDCD1 +7785 
exon5 (CT), CD28 int3(TT)/IFNG int1(AA)/ICOS 1564 3’UTR (TT)) (p<0,01). 
Entretanto, a contribuição do terceiro polimorfismo (TNFA, ICOS, or PDCD1) não 
foi confirmada (p=0,1). Confirmamos maior frequência, em pacientes, da 
combinação CD28(TT)/IFNG(AA) nos três grupos juntos, e observamos uma 
contribuição principal desta combinação na associação com a doença (OR = 2,07, 
p=0,0011). 2) A expressão intra-tumoral de GZMB estava aumentada em biópsias 
de pacientes com estadio IIIB que apresentaram uma evolução clínica ruim 
(p=0,034). A expressão gênica das moléculas CD28, ICOS, ICOSL, CD80, CTLA4 
e CD86 não mostrou diferenças significantes entre as biópsias de pacientes de 
grupos de evolução clínica boa e ruim. Conclusões: 1) Nossos resultados 
sugerem efeito epistático entre os genes CD28 e IFNG na susceptibilidade do 
câncer de colo uterino. Outros trabalhos em estudos independentes aplicando 
abordagem multi-locus são importantes para a elucidação da contribuição de 
polimorfismos genéticos para a susceptibilidade a esta doença. Além disto, o 
algoritmo desenvolvido pode ser aplicado a estudos sobre fatores genéticos de 
susceptibilidade a outras doenças complexas. 2) Altos níveis de mRNA de GZMB 
em tumores no estádio IIIB  correlacionaram-se com menor sobrevida livre do 
tumor nos 6 meses após o tratamento. A expressão deste gene, se os resultados 
obtidos forem confirmados por um estudo independente, pode vir a se tornar um 
marcador de prognóstico para resposta a tratamento de carcinoma de colo 
uterino. 
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APRESENTAÇÃO 
 
 
  A padronização das teses é uma preocupação antiga na pós-
graduação na área da saúde. Nos últimos anos, há um movimento no sentido de 
alterar a estrutura das teses tradicionais para um modelo que inclua um ou mais 
artigos a serem enviados para publicação em periódicos especializados. 
  Na Universidade Federal de São Paulo – Escola Paulista de Medicina 
muitos Programas de Pós-graduação adotam como modelo de tese o sugerido por 
Rother e Braga (2001)1. 
  A presente tese foi elaborada no modelo aprovado pela Comissão de 
Ensino e Pós-graduação do Programa de Pós-graduação em Microbiologia e 
Imunologia da UNIFESP-EPM, sendo constituída por: 
   1. Fundamentação Científica; 
   2. Anexos. 
  Na Fundamentação Científica são abordados os artigos publicados 
relacionados ao tema em questão, apresentando informações da literatura 
importantes para a justificativa da pesquisa, além de descrever os métodos 
utilizados de forma mais detalhada do que é possível em um artigo científico. 
Apresenta, também, a justificativa e o objetivo do estudo, a seqüência com que os 
resultados foram obtidos seguidos da discussão e conclusão, sendo finalizada com 
as respectivas referências bibliográficas. Nos anexos, estão inseridos um artigo 
publicado, dois artigos enviados para a publicação, trabalhos apresentados em 
congressos e publicados e dados originais do estudo. 
  O artigo científico foi elaborado segundo as normas do periódico cujo 
trabalho foi submetido. 
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1 Rother ET, Braga MER. Como elaborar sua tese: estrutura e referências. São Paulo; 2001 
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Abstract 
Background  
 Cervical cancer is a complex disease with multiple environmental and genetic determinants. 
The most important environmental factor is infection by high-risk types of human papillomavirus 
(HPV). Considering that only a small proportion of HPV-infected women develop cervical cancer, 
polymorphisms in immune response genes that might be involved in virus elimination, or in the 
immune response against the tumor, are considered important candidates to influence cervical cancer 
susceptibility.  
Results 
 In the present study we aimed to search association between polymorphisms in immune 
response genes and cervical cancer, using both single-locus and multi-locus analysis approaches. A 
total of 14 SNPs (Single Nucleotide Polymorphisms) distributed into CD28, CTLA4, ICOS, PDCD1, 
FAS, TNFA, IL6, IFNG, TGFB1 and IL10 genes were determined in patients and healthy individuals 
from three independent case/control sets: the first two sets comprised White individuals (one group 
with 82 cases and 85 controls, and the other with 83 cases and 85 controls) and the third was 
constituted by Non-White individuals (64 cases and 75 controls). No significant association was 
observed with any individual SNP. The multi-locus analysis revealed higher frequencies, in cancer 
patients, of three three-genotype combinations (CD28+17(TT)/IFNG+874(AA)/TNFA-308(GG), 
CD28+17(TT)/IFNG(AA)/PDCD1+7785(CT), and CD28 +17(TT)/IFNG+874(AA)/ICOS+1564(TT) 
(p<0.01, Monte Carlo simulation). Noticing that all these three genotype combinations contained two 
genotypes in common, i.e. CD28(TT) and IFNG(AA), we hypothesized that this two-genotype 
combination could have a major contribution to the observed association. To address this question, 
we analyzed frequencies of CD28(TT),IFNG(AA) genotype combination in the three groups combined 
and observed its increase in patients (p=0.0011 by Fisher’s exact test). In a second Monte Carlo 
simulation of three-genotype combinations where CD28 (TT) and IFNG (AA) were always present, we 
verified that the contribution of a third polymorphism did not reach statistical significance (p=0.1). 
Conclusions 
 Further analysis suggested that gene-gene interaction between CD28 and IFNG might be 
important for susceptibility to cervical cancer. 
Background 
There is overwhelming evidence that prolonged infection with oncogenic human 
papillomavirus is the major factor associated with development of cervical cancer [1]. However, 
considering that only a relatively small proportion of infected women develop cervical cancer, it is 
conceivable that other environmental and/or genetic factors play a role in the susceptibility [2]. Since 
the immune response has an important role in the defense against the virus, as well as against the 
tumor, polymorphisms in genes that potentially affect the immune response are candidates to 
influence the susceptibility to cervical cancer. 
A series of publications on polymorphisms of HLA class II genes and cervical cancer and/or 
its precursor lesions, cervical intraepithelial neoplasia (CIN), show that some HLA alleles are 
associated with protection, while others are associated with susceptibility  [3–10]. These associations 
are probably explained by the role of HLA II molecules in presenting viral- or tumor- derived epitopes 
to T CD4+ cells. More recently, interesting findings were reported concerning resistance/susceptibility 
to cervical cancer mediated by combinations of killer immunoglobulin-like receptor (KIR) and their 
HLA class I ligands [11]. 
As polymorphisms in genes coding for cytokines, cytokine receptors, co-stimulatory 
molecules may affect the immune response [12–14], they are natural candidates to influence the 
susceptibility to various diseases, including cancer.  
The majority of the studies of association between immune response genes and cervical 
cancer have analyzed single nucleotide polymorphisms (SNPs) in genes coding for tumor necrosis 
factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 6 (IL-6), interleukin 10 (IL-10), and 
transforming growth factor beta (TGF-β) [15–18]. Although some significant associations have been 
reported in some studies, they were not consistently confirmed in other studies [19–23].  
Bearing in mind that molecules involved in the immune response do not act in isolation, but 
form a complex network of interacting proteins, the net immunologic response is most probably the 
product of variation in many polymorphic genes. Therefore, it is of great importance to test the 
combination of polymorphisms in different genes as a risk factor for diseases [24–27]. Any multi-locus 
approach, however, directly or indirectly faces the problem that has been referred as “curse of 
dimensionality” because, although the number of polymorphisms under study may not be very large, 
the number of possible combinations between them turns to be extremely high. Some statistical 
approaches for this problem were recently reviewed [28]. 
 The purpose of this study was to investigate association between invasive cervical cancer and 
polymorphisms in genes coding the following immune response molecules: CD28, CTLA-4 (cytotoxic 
T-lymphocyte-associated protein 4), ICOS (inducible T cell co-stimulator), PDCD1 (programmed cell 
death receptor-1, also called PD-1) FAS, TNFα, IL-6, IFNγ, TGFβ1 and IL-10. In addition to the 
analysis of association with each polymorphism, we searched for association with two- and three-
polymorphism combinations, utilizing a new statistical approach. 
 
Materials and methods   
Patients and study design 
The patients were Brazilian women with invasive squamous cell carcinoma of the uterine 
cervix diagnosed at the Department of Gynecology of São Paulo Hospital, São Paulo, Brazil and 
Cancer Hospital of Uberlândia, Brazil. The controls comprised ethnically matched Brazilian healthy 
unrelated individuals.  
Three independent case-control sets were constituted. Case-control sets # 1 (82 cases and 
85 controls) and # 2 (83 cases and 85 controls) comprised White individuals, while set # 3 (64 cases 
and 51 to 75 controls, depending on the polymorphism) was constituted by non-Whites (Mulattos and 
Blacks). The ethnic classification was made by external phenotypic characteristics, as described in a 
publication of our group describing the frequencies of CD28, CTLA4, and ICOS polymorphisms in 
healthy individuals from three Brazilian ethnic groups [29].  
The Medical Ethics Committee from the Federal University of São Paulo and the Federal 
University of Uberlândia approved the study (#1208/01, #035/01), and written informed consent was 
obtained from all participants.  
 
Genotyping 
  Genomic DNA was extracted from EDTA preserved peripheral blood using the 
dodecyltrimethylammonium bromide/hexadecetyl trimethylammonium bromide (DTAB/CTAB) method 
[30]. Subjects were genotyped for 14 polymorphisms. PCR-RFLP was applied to detect the CD28 
intron 3 (+17 T>C), CTLA4 promoter (-319 C>T), CTLA4 exon 1 (+49 A>G), ICOS 3’UTR (+1564 
T>C), PDCD1 exon 5 (+7785 C>T) and FAS promoter (-670 G>A) SNPs.  Each PCR reaction was 
carried out in 25 µl containing Master Mix (Eppendorf, Hamburg, Germany), 0.1 mM solution of each 
of the specific primers (Table S1) and 100 ng of genomic DNA. The cycling profile was: 95oC for 45 
seconds, annealing for 30 seconds at temperatures shown in additional data file 1, 72oC for 30 
seconds, 40 cycles. The PCR products were then incubated with the appropriate restriction enzymes 
at 37oC, overnight. DNA fragments were visualized on 2.5% agarose gels stained with ethidium 
bromide. The assignments of SNP genotypes were confirmed in 10% randomly selected samples 
from each genotype by direct sequencing in an Applied Biosystems sequencer (ABI PRISM TM, Model 
3100 Avant). TNFA promoter (-308 G>A), IL6 promoter (-174 G>C), IFNG intron 1 (+874 A>T), 
TGFB1 codon 10 (+869 T>C), codon 25  (+915 G>C) and IL10 promoter (-1082 A>G), (-819 C>T), (-
592 C>A) SNPs were determined by polymerase chain reaction with sequence specific primers (PCR-
SSP), using the “Cytokine Genotyping Tray” (One Lambda, Inc, Canoga Park, CA). PCR conditions 
were as indicated by the manufacturer; the PCR products were then visualized by eletrophoresis in 
2.5% agarose gel. 
 
Hardy-Weinberg equilibrium and linkage disequilibrium testing 
Goodness-of-fit test to Hardy-Weinberg equilibrium was performed by calculating expected 
frequencies of each genotype and comparing them with the observed values. The false discovery rate 
(FDR) method [31] was used to correct the significance level of the Hardy-Weinberg equilibrium 
testing. Linkage Disequilibrium (LD) between two SNPs was calculated by Arlequin software [32].  
 
Statistics: single and multi-locus association analysis 
 Comparisons of single allelic and single genotype frequencies (obtained by direct count) 
between cases and controls in each one of the three study sets were performed by the Fisher’s exact 
test and the χ2 test, respectively. We performed an adjustment for multiple testing using FDR (See 
supporting material). 
 In the multi-locus analysis, we used a new approach combining three independent case-
control groups to decrease the probability of finding spurious association. We compared the 
frequencies of combinations of two and three genotypes between cases and controls. The first step 
consisted in the selection of gene combination candidates by filtering two and three genotype 
combinations, using the delete-d-jackknife method [33] in each of the three study sets. Genotypes 
with frequencies less than 10% among cases or controls were not considered. This threshold was 
determined taking into account the smallest sample size included in our study (n=48, in control group 
3). The strength (S) of the association for each genotype combination was calculated by S = | P(fcase - 
fcontrol <0) - P(fcase - fcontrol >0) | and all associations with S >0.990 were filtered in each case-control 
set. Among the combinations filtered, the ones common to all three sets were selected. 
For estimating the probability of sorting, by chance, the same or a higher number of 
combinations of any two and/or three genotypes in common to all three sets, we applied the Monte 
Carlo simulation [34]. The construction of the simulated case and control groups was performed as 
follows: 1) the experimental case and control groups were merged into one group; 2) the frequencies 
of the genotypes were calculated in this group; 3) the genotypes of the simulated case and control 
groups were randomly generated according to the frequencies of each genotype in the merged group. 
Three simulated case-control sets were constructed; 4) the delete-d-jackknife method was applied in 
all these three simulated case and control sets, as describe before; 5) steps 3 and 4 were repeated a 
thousand times.  
 To investigate the nature of SNP-SNP interaction, we pooled all cases and all controls to 
generate a combined case-control set. The odds ratio (OR) and its 95% confidence interval (CI) were 
calculated (Fisher’s exact test) as a measure of the association between genotypes or genotype-
combinations and cervical cancer risk. The comparison between ORs was performed using Cochran´s 
Q-statistics [35]. In addition, we used bootstrap to estimate the value of Q-statistics using its 
bootstrapping mean [33]. The penalized logistic regression [36] also was applied in this analysis (See 
supporting material). 
 
Results 
No deviation from Hardy-Weinberg equilibrium was detected regarding any SNP, in patients 
or in controls. LD was detected between IL10 -1082 A and IL10 -819 C, IL10 -1082 A and IL10 -592 
T,  IL10 -819 C and IL10 -592 T, TGFB1 +869 T and TGFB1 +915 G in all control groups, confirming 
previous findings [37–39] and in all patient groups. In addition, LD was found between CD28 +17 C 
and CTLA4 -319 T, both in cases and in controls, confirming our previous finding in healthy 
individuals [40]. Considering the LD, SNPs at positions CTLA4 -319, IL10 -592, IL10 -819 and TGFB1 
+915 were excluded from the analysis. Thus, only 10 SNPs were included in the association analysis. 
Among the 14 SNPs studied, we did not find any association between any isolated SNP, and 
cervical cancer risk after correction for multiple testing using FDR. 
The delete-d-jackknife method revealed three three-genotype combinations with frequencies 
in patients higher than in controls, in all three case-controls sets: (CD28(TT)/IFNG(AA)/TNFA(GG), 
CD28(TT)/IFNG(AA)/PDCD1(CT) and CD28(TT)/IFNG(AA)/ICOS(TT) (Figure 1). The estimated 
probability of finding at least three any three-genotype combinations by chance in the three study 
sets, according to the Monte Carlo simulation, is <0.01.  
Noticing that all three genotype combinations contained two genotypes (CD28(TT)/IFNG(AA)) 
in common and a distinct third genotype (TNFA(GG), ICOS(TT), or PDCD1(CT)), we applied a second 
Monte Carlo simulation to estimate the probability of finding by chance at least three three-genotype 
combinations containing the first (CD28(TT)) and second (IFNG(AA)) genotypes always present and 
any distinct third-genotypes. The simulation showed that this probability was 0.1. Therefore, we 
excluded the TNFA, ICOS, and PDCD1 SNP from the interaction analysis. 
Next, we calculated the overall frequency of CD28(TT)/IFNG(AA) in patients and controls, 
considering all the individuals that were included in the study (229 patients and 193 controls) and 
observed a higher frequency of this genotype combination in patients (34%) than in controls (20%) 
(Fisher’s exact test: p=0.0011; OR=2.08, 95%CI:1.33–3.24 Figure 2). 
Thereafter, to analyze the nature of the interaction effect between CD28 and IFNG, we 
investigated the effect of CD28(TT), in the population stratified according to the presence or absence 
of IFN(AA) genotype (Figure 3A). We observed significantly higher frequencies of CD28(TT) in cases 
than in controls in the presence of IFNG(AA) (OR=2.84 95% CI=1.42-5.66, p=0.003) while no 
difference (OR=1.35 95% CI=0.79-2.30, p=0.2815) was detected in the absence of IFNG(AA). To be 
certain of the presence of interaction effect, we compared ORs in the presence or absence of 
IFNG(AA) and observed higher OR when this IFNG genotype was present (2.84 vs 1.35, p= 0.05). As 
expected, we observed similar result analyzing frequencies of IFNG(AA) in the presence or absence 
of CD28(TT) (Figure 3B). The penalized logistic regression also confirmed the presence of the 
interaction between the two polymorphisms (p=0.02; see details in the supplemental material). 
 
Discussion 
The aim of the present study was to search for association of single and/or combined 
polymorphisms in 10 immune response genes with cervical cancer. 
In agreement with the majority of previous association studies between cervical cancer and 
FAS, TNFA, IFNG, and IL10 polymorphisms [41–44] we did not find any association between any of 
these polymorphisms and cervical cancer risk. Also our study is the first investigation of CD28, ICOS, 
PDCD1 or CTLA4 polymorphisms in cervical cancer patients. Importantly, we have revealed that the 
CD28(TT)/IFNG(AA) combination is associated with the disease.  
In order to identify associations of two- or three-genotype combinations with cervical cancer 
we applied a new statistical analysis comprising three steps: 1) use of a procedure (delete-d-
jackknife) for sorting out combinations of any two- and/or three-marker combination that could be 
associated to cervical cancer in each one of the three case-control sets; 2) selection of the 
combinations in common to all three case-control sets; 3) calculation of the probability of finding the 
common combination pattern by chance (Monte Carlo simulation). The major advantage of applying 
this new approach is its ability to increase the searching capacity (i.e. power) of the test (first step), 
while keeping first type error low by accepting only associations that appeared in all three 
independent case-controls sets. (second step). 
Although the multi-locus analysis herein reported uses a combinatorial method based on multi 
dimensional reduction method (MDR) [45], the direct comparison of the efficiency of these two 
procedures could not be performed in our dataset. The first problem is that MDR does not accept 
missing values and this constrain decreases the number of individuals available for the analysis in our 
dataset. The main difference between MDR and our analysis is that, while the first was devised for 
finding the best combination in a single dataset, the second is based on the consistency of findings in 
three separate datasets. In addition, we think MDR method does not provide an adequate solution for 
the multiple hypothesis problem. 
Models that compare several genotype combinations generate a series of hypothesis and, 
therefore, increase the number of false discoveries. However, it is not clear how this problem can be 
addressed using traditional statistical methods (e.g. false discovery rate) because those are 
applicable only in situations where the hypotheses are independent. This is not the case of multi-locus 
analysis and there is no widely accepted analytical solution for this problem. Thus, we employed an 
experimental statistical approach to control for the falsely included genotypes combinations in the 
model. The results of our screening were significant (Monte Carlo simulation, p<0.01), i.e., 
CD28(TT)/IFNG(AA)/TNFA(GG), CD28(TT)/IFNG(AA)/PDCD1(CT) and 
CD28(TT)/IFNG(AA)/ICOS(TT) genotype combinations are candidates to be associated with cervical 
cancer. 
Noticing that CD28(TT)/IFNG(AA) genotype combination was present in all three three-
genotype combinations we wondered why this two-genotype combination was not sorted out as 
significant by the delete-d-jackknife procedure. In order to understand this issue, we looked at the 
frequencies of CD28(TT)/IFNG(AA) genotypes combination in all three case-controls sets. We 
observed that, although  these frequencies were higher in cases than in controls in all three sets 
(Figure 2), this association was not sorted out in case-control set # 2, because the strength of the 
association was lower (S = 0.985) than the adopted cut-off (S > 0.990). A reasonable explanation is 
that the adopted cut-off took into account the number of all hypothesis (405 and 3240 hypothesis for 
two- and three-genotype combinations respectively). Due to this high number of three-genotype 
combinations, the cut-off became very rigorous to allow for some two-genotype combinations to be 
sorted out. We concluded that this association was probably real but did not appear due to too strict 
criteria. 
Although we excluded the TNFA(GG), ICOS(TT), or PDCD1(CT) from the interaction analysis, 
the results suggested (p=0.10) that, besides CD28(TT)/IFNG(AA), there might exist some effect of an 
additional genotype. However, sample size in the present study does not allow the confident analysis 
of the effect of the third locus. 
Considering that CD28 +17 T and CTLA4 -319 C alleles are in linkage disequilibrium, we 
excluded the CTLA4 -319 polymorphism from our initial analysis. But, after observing the association 
of cervical cancer with CD28(TT)/IFNG(AA), we substituted CD28 +17 by CTLA4 -319 and performed 
a Fisher’s exact test in the total case-control set. Although, as expected, this association was also 
significant (p=0.0398), it was weaker (OR= 1.54; 95% CI=1.025 - 2.325) than the association where 
CD28 (TT) was present (OR=2.08; 95% CI=1.33–3.24, p=0.0011). Therefore, we concluded that the 
CD28(TT)/IFNG(AA) combination, rather than CTLA4(CC)/IFNG(AA) combination, is a better marker 
for susceptibility to cervical cancer. 
In order to examine the interaction effect between CD28(TT) and IFNG(AA) genotypes we 
compared the frequency of CD28(TT) between patients and controls stratified for the presence of 
IFNG(AA) genotype and vice-versa (Figure 3). This allows us to illustrate interaction as well as to 
perform statistical evaluation of the effect. Furthermore, when using penalized logistic regression 
(Park, 2007)[36] we have also observed the interaction of CD28 and IFNG, thus confirming our finding 
with another method for interaction analysis. 
The biological relationship between CD28/IFNG interaction and cervical cancer may rely on 
two different mechanisms. The first potential mechanism is the effect of product of one gene on the 
product of the other gene. This possibility is supported by some pieces of evidence. Voigt and 
colleagues [46] reported that in CD28-deficient mice, IFN-γ-producing CD8+ T cells were not only 
reduced in number but also less potent in lysing their respective target cells. It is also known that the 
regulation of NFκB transcription family in T-cell involves signaling through CD28 [47]. NFκB may not 
only regulate the induction of IFN-γ-induced genes but also the antiviral and immunomodulatory 
activities of IFN-γ [48].  
The second mechanism might be an independent functional contribution of each one of 
genotypes, but the presence of both seems to be necessary to trigger the studied phenotype. Indeed, 
there is an abundant literature showing that genetic factors substantially influence production of 
cytokines and that anti-inflammatory cytokine profile may contribute to the disease process [49]. The 
presence of allele A on position +874 intron 1 of IFNG gene disables a putative NFKB binding site and 
can result in a lower level of IFN-γ production [50]. In addition, there is some evidence of a 
relationship between IFN-γ expression and HPV infection/cervical cancer. El-Sherif et al [51] 
demonstrated a decreased level of IFNG mRNA in HPV-16 associated epithelium and also that sub-
epithelial IFNG mRNA decreased with the progression of lesions. Although, we did not find any study 
addressing the question of the influence of CD28 +17 T>C polymorphism in CD28 mRNA or protein 
expression, this SNP is located near the splice acceptor site. Therefore, it could influence splicing 
events which, in turn, could affect CD28 signaling and T cell activation. We did not find in the literature 
any study concerning CD28 expression or polymorphisms in cervical cancer.  
Considering the fact that cervical cancer correlates with persistent HPV infection [52,53], it is 
important to note that the design of our study does not discriminate genetic association with cancer 
from association with persistent HPV infection. Thus, there is a possibility that we observed the 
association with persistent HPV infection that causes subsequent development of cervical cancer. 
 
Conclusions 
 In conclusion, our results showed an epistatic effect between CD28 and IFNG genes in 
susceptibility to cervical cancer, a finding that might be relevant for a better understanding of the 
disease pathogenesis. In addition, the novel analytical approach herein proposed might be useful for 
increasing the statistical power of future genome-wide multi-locus studies. 
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; CTLA4, cytotoxic T-
lymphocyte-associated protein 4; FAS, TNF receptor superfamily, member 6; FDR, false discovery 
rate; HLA, human leukocyte antigens; HPV, human papillomavirus; ICOS, inducible T-cell co-
stimulator; IFNG, interferon, gamma; IL10, interleukin 10; IL6, interleukin 6; KIR, killer 
immunoglobulin-like receptor; LD, linkage disequilibrium; NFκB, nuclear factor-kappa beta; PCR-
RFLP, polymerase chain reaction - restriction fragment length polymorphism; PCR-SSP, polymerase 
chain reaction-sequence specific primer; PDCD1, programmed cell death 1; SNP, single nucleotide 
polymorphism; TGFB1, transforming growth factor beta,1; TNFA,  tumor necrosis factor alpha. 
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Additional data files  
The following additional data are available with the online version of this paper. Additional data file 1 
is a table listing primers sequences, annealing temperatures and restriction endonucleases used for 
genotyping. Additional data file 2 is a description of penalized logistic regression method. Additional 
data file 3 is a table comparing single allelic and single genotype frequencies between cases and 
controls in each one of the three study sets. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Revealing genotype combinations associated with cervical cancer in three case-control sets. 
Each circle represents the number of combinations of two and three genotypes that passed the 
filtering criteria in each case-control set. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Characteristics of CD28(TT)/IFNG(AA) genotype association to cervical cancer in the 
three case-control sets. X-axis represents odds ratio (OR) scale. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. CD28(TT) and  IFNG(AA) polymorphisms are associated to cervical cancer only in the 
presence of each other. (A), analysis of CD28(TT) association in the presence or absence of 
IFNG(AA). (B), analysis of IFNG(AA) association in the presence or absence of CD28(TT). X-axis 
represents odds ratio (OR) scale. 
  
  Additional data file 1 
 
 
  Table 1 Primers, annealing temperatures and restriction endonucleases used for genotyping. 
 
Polymorphisms   Sense                    Antisense      Annealing Restriction
    primer                    primer                  temperature              
enzyme 
 
CD28 Int3T>C                 5’TTTTCTGGGTAAGAGAAGCAGCGC 3’          5’GAACCTACTCAAGCATGGGG 3’                  58OC              Eco 47RIII 
CTLA4 - 318C>T             5’AAATGAATTGGACTGGATGGT 3’                  5’TTACGAGAAAGGAAGCCGTG 3’                   60 OC            Mse I 
CTLA4 +49 A>G              5’CACGGCTTCCTTTCTCGTAA 3’                     5’CCCTGGAATACAGAGCCAGC 3’                    63OC             Bbv I 
ICOS 3’UTR 1564 T>C   5’ TTACCAAGACTTTAGATGCTTTCTT 3’          5’GAATCTTTCTAGCCAAATCATATTC 3’           55OC             Alu I 
                               PDCD1 +7785 C>T          5’ AGACGGAGTATGCCACCATTGTC 3’             5’ AAATGCGCTGACCCGGGCTCAT 3’              50 OC            PvuII 
 
                               FAS -670 G>A                  5’ CTACCTAAGAGCTATCTACCGTTC 3’            5’ GGCTGTCCATGTTGTGGCTGC 3’                62 OC            Mva I 
 
 
  
Additional data file 2 
 
 
 
Penalized Logistic Regression.  
 
For all calculations we used R package “stepPrl” created by Park & Hastie (2006). The logistic 
regression model is represented by the following formula  
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=
=
0
}|0{
}|1{
log  
where X is a matrix of predictors. Coefficients of regression model are usually estimated by maximum 
likelihood.  
In order to estimate coefficients of penalized logistic regression it is necessary to minimize the 
following function: 
2
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where l indicates the binomial log-likelihood, and λ is a positive constant.  
In order to choose the value of parameter λ Mee Young Park and Trevor Hastie (2006) implemented 
the cross-validation technique. We also used this solution with slight modification. In brief, keeping in 
mind that the cross validation technique is based on random division of data, we repeated the above 
procedure 100 times choosing 100 candidates values of parameter λ. After that, we selected a 
parameter λ as the mean of 100 obtained λ values during iterative procedure. Using set of candidate 
values λ = {0.01, 0.5, 1, 2, 3, 4} we observed λ ≈ 2. For CD28(AA) and IFNG(TT) using Akaike 
information criterion we obtained the following regression: 
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In parenthesis are p-values of corresponding coefficients.
 
 
 
Additional data file 3 
Table 2 Single allelic and single genotype frequencies between cases and controls in each one of the three study sets. 
Qui-square test and Fisher exact test were used to compare genotypes and alleles. Odds ratio (OR) and confident interval 
95% (95%CI) were determined. The p-values (parenthesis) were adjusted by FDR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1 Group 2 Group 3 SNPs 
Case 
(%) 
Control 
(%) 
 p 
value 
 (p-
adjust
ed) 
Case 
(%) 
Control 
(%) 
 p 
value  
(p-
adjust
ed) 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjusted) 
CD28 +17 n=82 n=72   n=83 n=74   n=64 n=48   
T/T 61 (0.74) 45 (0.63)   57 (0.69) 46 (0.62)   55 (0.86) 31 (0.65)   
T/C 16 (0.20) 19 (0.26)   22 (0.26) 23 (0.31)   9 (0.14) 16 (0.33)   
C/C 5 (0.06) 8 (0.11)  
0.2 
(0.40) 4 (0.05) 5 (0.07)  
0.6 
(0.93) 0 (0) 1 (0.02)  0.02 (0.28) 
             
CD28 +17 n=164 n=144   n=166 n=148   n=128 n=96   
T 138 (0.84) 109 (0.76)   136 (0.82) 115 (0.78)   119 (0.93) 78 (0.81)   
C 26 (0.16) 35 (0.24)  
0.08 
(0.28) 30 (0.18) 33 (0.22)  
0.4 
(1.40) 9 (0.07) 18 (0.19)  0.01 (0.14) 
             
CTLA4 
-319 n=82 n=73   n=83 n=73   n=65 n=49   
T/T 1 (0.01) 0  (0)   0 (0) 2 (0.03)   0 (0) 0 (0)   
T/C 15 (0.19) 13 (0.18)   15 (0.18) 9 (0.12)   2 (0.03) 6 (0.12)   
C/C 66 (0.80) 60 (0.82)  
0.6 
(0.84) 68 (0.82) 62 (0.85)  
0.2 
(1.40) 63 (0.97) 43 (0.88)  0.06 (0.42) 
             
CTLA4 
-319 n=164 n=146   n=166 n=146   n=130 n=98   
T 17 (0.10) 13 (0.09)   15 (0.09) 13 (0.09)   2 (0.02) 6 (0.06)   
C 147 (0.90) 133 (0.91)  
0.7 
(0.82) 151 (0.91) 133 (0.91)  
1.0 
(1.01) 128 (0.98) 92 (0.94)  0.07 (0.33) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1 Group 2 Group 3 SNPs 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjusted) 
Case 
(%) 
Control 
(%) 
 p value  
(p-adjusted) 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjust) 
CTLA4 
+49 n=82 n=72   n=83 n=76   n=65 n=49   
A/A 46 (0.56) 31 (0.43)   37 (0.45) 45 (0.59)   26 (0.40) 30 (0.61)   
A/G 26 (0.32) 35 (0.49)   40 (0.48) 22 (0.29)   30 (0.46) 13 (0.27)   
G/G 10 (0.12) 6  (0.08)  0.1 (0.28) 6 (0.07) 9 (0.12)  0.04 (0.56) 9 (0.14) 6 (0.12)  
0.07 
(0.33) 
             
CTLA4 
+49 n=164 n=144   n=166 n=152   n=130 n=98   
A 118 (0.72) 97 (0.67)   114 (0.69) 112 (0.74)   82 (0.63) 73 (0.75)   
G 46 (0.28) 47 (0.33)  0.4 (0.80) 52 (0.31) 40 (0.26)  0.4 (1.87) 48 (0.37) 25 (0.25)  
0.08 
(0.28) 
             
FAS -670 n=82 n=82   n=83 n=83   n=64 n=49   
GG 23 (0.28) 20 (0.24)   15 (0.18) 18 (0.22)   22 (0.34) 12 (0.25)   
GA 42 (0.51) 44 (0.54)   40 (0.48) 45 (0.54)   35 (0.55) 26 (0.53)   
AA 17 (0.21) 18 (0.22)  0.8 (1.02) 28 (0.34) 20 (0.24)  0.4 (1.12) 7 (0.11) 11 (0.22)  0.2 
(0.56) 
             
FAS -670 n=164 n= 164   n=166 n=166   n=128 n=98   
G 88 (0.54) 84 (0.51)   70 (0.42) 81 (0.49)   79 (0.62) 50 (0.51)   
A 76 (0.46) 80 (0.49)  0.7 (0.89) 96 (0.58) 85 (0.51)  0.3 (4.20) 49 (0.38) 48 (0.49)  0.1 
(0.23) 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1 Group 2 Group 33 SNPs 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjusted) 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjusted) 
Case 
(%) 
Control 
(%) 
 p value 
 (p-
adjust) 
TNFA -308  n=82 n=85   n=83 n=84   n=64 n=74   
GG 54 (0.66) 71 (0.84)   63 (0.76) 65 (0.78)   47 (0.73) 48 (0.65)   
GA 24 (0.29) 13 (0.15)   19 (0.23) 17 (0.20)   16 (0.25)  25 (0.34)   
AA 4 (0.05) 1 (0.01)  
0.02 
(0.28) 1 (0.01) 2 (0.02)  
0.8 
(1.02) 1 (0.02) 1 (0.01)  
0.5 
(0.88) 
             
TNFA -308  2n=164 2n=170   2n=166 2n=168   n=128 n=148   
G 132 (0.80) 155 (0.91)   145 (0.87) 147 (0.88)   110 (0.86) 121 (0.82)   
A 32 (0.20) 15 (0.09)  
0.007 
(0.10) 21 (0.13) 21 (0.12)  
1.0 
(1.08) 18 (0.14) 27 (0.18)  
0.4 
(0.62) 
             
IL6-174 n=82 n=85   n=83 n=84   n=64 n=74   
GG 31 (0.38) 43 (0.51)   43 (0.52) 45 (0.54)   42 (0.66) 49 (0.67)   
GC 44 (0.54) 29 (0.34)   33 (0.40) 33 (0.39)   18 (0.28) 21 (0.28)   
CC 7 (0.08) 13 (0.15)  
0.03 
(0.14) 7 (0.08) 6 (0.07)  0.9 (0.9) 4 (0.06) 4 (0.05)  
0.9 
(0.9) 
             
IL6-174 2n=164 2n=170   2n=166 2n=168   2n=146 2n=148   
G 106 (0.65) 115 (0.68)   119 (0.72) 123 (0.73)   102 (0.70) 119 (0.80)   
C 58 (0.35) 55 (0.32)  
0.5 
(0.78) 47 (0.28) 45 (0.27)  
0.8 
(1.02) 44 (0.30) 29 (0.20)  
0.043 
(0.30) 
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Abstract 
 
The aim of this study was to assess, in invasive cervical carcinoma, expression levels of 
genes involved in the immune response and seek correlation to response to treatment. To this end, 
expression levels of genes coding for costimulatory molecules (CD28, CTLA4, ICOS, ICOSL, CD80 
and CD86) and for granzyme B were assessed by real-time RT-PCR in pre-treatment tumor 
fragments. The treatment consisted of radiotherapy only or radiotherapy plus chemotherapy. During 
the six-month follow-up after treatment, eight patients presented tumor (poor outcome group) and ten 
survived free-of tumor (good outcome group). The only gene whose expression was different between 
these groups was granzyme B, being the expression levels higher in patients with poor outcome 
(medians of 4.991 vs 0.578 relative units, p=0.034), similar to what has been described in some other 
tumors. Further evaluation, in adequately powered prospective studies is warranted to confirm the 
data and to translate this observation to the clinical setting. 
 
Introduction 
 
Worldwide, carcinoma of the uterine cervix is the second most common cause of cancer-related 
death in women (1). Although infection with oncogenic types of human pappilomavirus (HPV) is 
considered the main risk factor for this malignancy (2,3), other variables are considered to play a role, 
since only a minority of infected women develops cervical cancer (4). There is evidence that a 
deficient immune response to the virus and/or to the tumoral cells is an important factor in the 
development and/or progression of cervical cancer (5).  
Cervical cancer is usually staged according to the FIGO (International Federation of Gynecology 
and Obstetrics) system that takes into account the histological type and clinical stage and correlates 
to disease outcome.  Depending on the FIGO stage, the patients are treated with surgery or/and 
radiotherapy alone, or combined with chemotherapy (6). Effective treatment for cervical cancer is 
successful in about 80% of the cases of early-stage and in approximately 60% of cases of stage III 
disease (7). Stage III is characterized by tumor extension to pelvic wall and/or involvement of the 
lower third of vagina and/or hydronephrosis or nonfunctioning kidney (8).  
Although much attention has been given to define, in stage I/II tumors, molecular markers for risk 
or resistance to progression to invasive carcinoma, there are few studies focusing on markers for 
disease outcome after treatment of stage III disease (9,10). 
The purpose of the present study was to investigate whether expression levels of immune 
response genes in stage III cervical cancer biopsies before treatment would correlate with response 
to treatment. The genes selected for evaluation were genes coding for molecules involved in the 
costimulation of T cells (CD28, CTLA4, ICOS, ICOSL, CD80, CD86) and of the gene coding for 
granzyme B (GZMB), a mediator of the killing function of cytotoxic T lymphocytes (CTL) and NK cells 
(11).  
 
 
Material & Methods 
 
Patients & samples 
 
 The study comprised 18 patients with FIGO stage IIIB cervical carcinoma, followed in São 
Paulo Hospital and in Leonor Mendes Barros Hospital, São Paulo, Brazil. The protocol was approved 
by the Ethics Committee of the Federal University of São Paulo and informed consent was obtained 
from all patients. Disease clinical stage was classified according to FIGO criteria (12). The median 
age at diagnosis was 55 years (range: 30 to 72); 15 were Caucasians and three, non-Caucasians; 17 
had squamous cell carcinomas and one, adenocarcinoma. The treatment consisted of radiotherapy 
only or radiotherapy plus chemotherapy. Six months after the end of the therapy the patients were 
classified into two groups: (1) patients who had tumor or had died from the disease during the follow-
up period (poor outcome group, n=8) and (2) patients who had no tumor (good outcome group, n=10).  
 Biopsy specimens of the tumors for the gene expression study were obtained from patients at 
the time of diagnosis, before any anti-tumor therapy. Immediately after collection, samples were 
placed in vials containing 1 ml RNAlater (Ambion, Austin, TX), stored at 40C for up to 12 h, and then 
frozen at -800C. 
 
 
 
RNA isolation, RNA quality evaluation and reverse transcription 
 
Total RNA was isolated from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s protocol. The RNA integrity was assessed by Agilent 2100 Bioanalyzer 
using RNA 6000 Nano LabChip kit (Agilent Technologies, Waldbronn, Germany). All RNA samples 
used in this study had a 28S/18S ribosomal RNA ratio of at least 1.0. Using 1 µg of total RNA, cDNA 
synthesis was performed with oligo-(dT)12-18 primer and Superscript II H (Invitrogen, Carlsbad, CA) at 
420C for 60 min, followed by heating at 700C for 10 min. 
Quantitative real-time PCR 
  Primers were constructed using “Primer Express” software (Applied Biosystems Foster City, 
CA) based on reference mRNA sequences at Human Genome Browser, UCSC. The sequences of 
the primers for each gene studied are listed in Table 1. Real-time-PCR amplification reaction was 
carried out using 5.5 µl SYBR Green I Master Mix (Applied Biosystems, Foster City, CA), 125 nmol of 
each specific primer and 1 µl cDNA template in a total volume of 11 µl. PCR was performed in an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). For the signal 
detection, ABI Prism 7000 was programmed to an initial step of 10 min at 950C, followed by 40 
thermal cycles of 15 seconds at 950C, and at 600C for 1 minute. Using a pool of genomic DNAs of 15 
individuals, we checked for the absence of pseudogenes and contaminating genomic DNA 
amplifications. For quantification we used a cycle threshold (Ct) value against a standard curve 
constructed after amplification, in 10-fold serial dilutions, of a known number of copies of the template. 
All reactions were performed in triplicate. Target gene mRNA levels were normalized by the mRNA 
level of two reference genes (Deoxyhipusine synthase (DHPS) and PAP-associated domain 
containing 5 (PAPD5)) and the results were expressed as relative unites (RU), as previously 
described (13). The reference genes were selected among low-varying expression genes in 
preliminary cervical cancer microarray data from our laboratory, using a previously described 
algorithm (14).  
 
 
 
 
Statistical Analysis 
 
The relationship between outcome and quantitative and qualitative variables was analyzed using 
Student´s t test and Fisher’s exact test, respectively. For the comparison of mRNA levels between the 
two outcome groups, we used the non parametric Mann-Whitney test. P values ≤ 0.05 were 
considered significant. 
 
Results 
 
Poor and good outcome patients did not differ significantly regarding age (medians: 55 vs 53), 
proportion of Caucasians patients (100 vs 70%), proportion of squamous cell carcinomas (88 vs 
100%) or proportion of patients treated with radiotherapy only, without chemotherapy (88% vs 80%).  
Regarding mRNA expression, we have first confirmed, by RT-PCR, that the expression levels 
of the reference genes (DHPS and PAPD5, selected from microarray data) did not differ between the 
biopsy samples from patients with poor and good outcome after treatment (data not shown), and then 
we used them to normalize the expression of target genes in each sample. No significant differences 
between the two clinical outcome groups were observed regarding expression levels of CD28, 
CTLA4, ICOS, ICOSL, CD80 and CD86 genes, while mRNA levels of GZMB were higher in samples 
from patients with poor outcome (medians of 0.578 vs 4.991 RU, p=0.034) (Table 2). The distribution 
of GZMB mRNA levels in each group is shown in figure 1.  
 
Discussion 
 
 The prediction of response to cancer treatment is a field of extensive investigation (15,16). 
These studies may not only establish risks for different outcomes but also could unravel factors or 
mechanisms that may lead to the development of more effective treatments.  
 In the present study we have explored the expression levels of genes coding for costimulatory 
molecules (CD28, CTLA4, ICOS, ICOSL, CD80 and CD86) and for granzyme B in invasive cervical 
carcinoma as markers for the response to treatment. The results showed that the only gene whose 
expression correlated with disease outcome was granzyme B, being the expression levels higher in 
patients with poor outcome. This result was unexpected since perforin/granzyme-induced apoptosis is 
considered the main pathway used by cytotoxic lymphocytes to eliminate virus-infected or 
transformed cells (17). Furthermore, it has been shown that increased numbers of GZMB-positive 
CTLs at the invasive border is a reliable independent prognostic factor of survival in patients with 
endometrial carcinoma (18). 
 In cervical intraepithelial neoplasia, higher numbers of GZMB-positive cells at the moment of 
treatment were observed in cases without recurrence than in those with disease recurrence (19). 
Therefore, our initial expectation was that high intra-tumor granzyme B expression would be 
associated with a favorable response to cervical cancer treatment. However, the observed results, 
showing the opposite, are in line with other studies. It is interesting to note that the same study cited 
above that showed that recurrence of cervical intraepithelial neoplasia was lower in cases with higher 
numbers of CTLs, showed a higher number of GZMB-positive cells in carcinoma than in intraepithelial 
neoplasia (19). Similar observations had already been reported by other authors who suggested that 
in some carcinomas proper activation of CTLs occurs, but probably local factors or immunoselection 
of resistant neoplastic cells inhibit a proper response of CTLs to these neoplastic cells (20).  
 The relationship between increased GZMB mRNA level and an unfavorable clinical outcome 
has also been described in other malignancies, as nodal anaplastic large cell lymphoma (21), 
Hodgkin’s lymphoma (22,23) and nasopharyngeal carcinoma (24). A very interesting observation that 
might be related to our data is that absence of HPV in cervical cancer biopsies before treatment is 
associated with poor patient survival after treatment (25,26,27).  As an explanation for the higher 
survival rate in the patients with HPV-positive tumor, it was suggested that integration of HPV may 
result in more unstable DNA, therefore, rendering the tumor more sensitive to radiotherapy, the major 
treatment for this cancer (28). Therefore, we may speculate that an explanation for our observation of 
increased GZMB mRNA level in the group of patients with poor response to treatment is that a more 
active immune response, evidenced by GZMB expression, could lead to greater virus elimination. 
Importantly, the relation to HPV load in CIN is also opposite to the cervical invasive cancer, i.e. higher 
viral load is associated with higher CIN severity (29,30).  Thus, it seems that progression of pre-
cancer lesions and invasive cancer may have very different mechanisms. 
In conclusion, our results suggest that high pre-treatment granzyme B mRNA level is a 
potential marker for stage IIIB cervical cancer poor response to therapy. Further evaluation, in 
adequately powered prospective studies is warranted to confirm the data and to translate this 
observation to the clinical setting. 
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Table 1. Primer sequences used in real-time PCR  
 
Gene Primer sequence (5’-3’) PCR product (bp) 
CD28 
F: CCTCCTCCTTACCTAGACAATGAGAA 
R: AGCCAGGACTCCACCAACCA 
138 
ICOS 
F: AAAGTAACTCTTACAGGAGGATATTTGCAT 
R: GGCTGCACATCCTATGGGTAAC 
90 
ICOSL 
F: GTGAACATTGGCTGCTGCAT 
R: GCGTTTTTCTCGCCGGTACT 
131 
CTLA4 
F: CTCTGGATCCTTGCAGCAGTTAGT 
R: ATAAGGCTGAAATTGCTTTTCACA 
164 
CD80 
F: CCTGATAACCTGCTCCCATCCT 
R: CTTTCCCTTCTCAATCTCTCATTCC 
134 
CD86 
F: GGATTACAGCTGTACTTCCAACAGTT 
R: CTTCCCTCTCCATTGTGTTGGTT 
130 
GrB 
F: CGCCATTATTACGACAGTACCATT 
R: CTGGGCCACCTTGTTACACA 
111 
DHPS 
F: GACTGGCTGATGCCCATTCT 
R: CCGTCTGTAAGTGCGGGACTA 
176 
PAPD5 
F: TTGGAGTCCTCTCAGGCAGTT 
R: TGGAAGCCTTTGCTGGAAGAAC 
122 
 
Table 2. Intra-tumoral mRNA levels of seven immune response genes in patients with stage IIIB 
cervical cancer  
 
mRNA (RU) median values 
 
Gene 
Good outcome # 
N= 10 
Poor outcome# 
N= 8 
CD28 0.155 0.257 
ICOS 0.129 0.167 
ICOSL 0.135 0.209 
CTLA4 0.009 0.013 
CD80 0.139 0.266 
CD86 0.244 0.400 
Granzyme B 0.578 4.991* 
RU: relative units (mRNA levels normalized by mRNA level of two reference genes (DHPS and 
PAPD5)  
# Good and poor outcomes considering 6-month disease-free survival after treatment.  
*p=0.034 (Mann-Whitney test)  
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Figure 1. Distribution of granzyme B (GZMB) mRNA levels in biopsies from good (n=10) and poor 
(n=8) outcome groups of patients with stage IIIB cervical cancer. Quantification of mRNA was 
performed using real-time PCR and the results are expressed as relative units (RU). The lines 
represent the median values. GZMB mRNA levels were significantly higher in the poor clinical 
outcome group (p=0.034, Mann-Whitney test).  
 
 
 
 
7.2. Resumos apresentados em congressos 
 
 
 
7.2.1. Anexo #1  
 
 
Cytokine gene polymorphisms in brazilian and non-brazilian ethnic groups 
Amador Goncalves-Primo ,Natalia Shulzhenko, Andrey Morgun, Gisele F Rampim, Karina L Mine, 
Silvia Daher and Maria Gerbase-DeLima 
 
Resumo apresentado no XXVII Congresso Anual da Sociedade Brasileira de Imunologia/2002 e 
resultados parciais foram publicados no periódico Human Immunology volume 65, p. 878-879, em 
setembro/outubro de 2004 
 
 
 
CYTOKINE GENE POLYMORPHISMS IN BRAZILIAN AND NON-BRAZILIAN ETHNIC 
GROUPS 
Amador Goncalves-Primo 1 ,Natalia Shulzhenko 1, Andrey Morgun 1, Gisele F Rampim 
1,Karina L Mine1 , Silvia Daher 1 and Maria Gerbase-DeLima 1. 1Pediatrics, Federal 
University of Sao Paulo, Sao Paulo, SP, Brazil.  
 
The study of cytokine gene polymorphisms in different ethnic groups is relevant for 
anthropologic studies, as well as for providing a database for investigations concerning their 
influence on immune responses and on susceptibility to diseases. Frequencies of TNF-α (-
308 G->A), IL-10 (-1082 G->A, -819 C->T, -592 C->A), IL-6 (-174 G->C), IFN-γ (+874 A->T), 
and TGF β1 (+869 T->C, +915 G->C) single nucleotide polymorphisms (SNPs) were 
determined in Brazilian White (n=107), Mulatto (n=100) and Black (n=71) healthy individuals. 
SNPs frequencies in non-Brazilian Whites and non-Brazilian Blacks were compiled from 46 
published studies. Allele frequencies were obtained by direct counting and are shown in the 
table. 
 
Allele frequencies (%) of the studied cytokine gene polymorphisms in different ethnic 
groups 
Ethnic group TNF- α IFN- γ IL-6 TGF- β1 TGF- β1 IL-10 IL-10 
  +308 A 
+874 
T 
-174 
C 
+869 C +915 C 
-1082 
G 
-819 T; -592 
A 
Non-Brazilian Whites 16.8 46.9 42.0 42.7 7.2 49.7 22.2 
Brazilian Whites 8.0 43.0 27.6 35.0 5.5 35.0 37.0 
Brazilian Mulattos 15.5 37.5 21.0 48.5 6.0 34.5 32.5 
Brazilian Blacks 12.3 28.7 16.2 45.6 8.0 39.7 35.3 
Non-Brazilian Blacks 13.6 28.2 7.4 49.0 13.0 35.2 41.5 
 
The differences between non-Brazilian Whites and non-Brazilian Blacks 
were statistically significant for all SNPs, except for +869 TGF- β1. 
Genetic distances were smaller between Brazilian Whites and Brazilian 
Mulattos (0.069) than between Brazilian Whites and non-Brazilian 
Whites (0.107), whereas the distances between  Brazilian Blacks and 
Brazilian Mulattos (0.048) and between Brazilian Blacks and non-
Brazilian Blacks (0.05) were similar. The largest genetic distance was 
observed between non-Brazilian Whites and non-Brazilian Blacks 
(0.178). The different racial distribution shown by this study for the 
majority of cytokine gene polymorphisms further emphasizes the 
importance of ethnical matching in disease association studies. 
 
 
7.2.2. Anexo #2  
 
 
 
Polymorphisms in ten immune response genes and susceptibility to cervical cancer 
Valeska B. Guzmán, Natalia Shulzhenko, Andrey Morgun, Luiz R. Goulart, Carmen R.N. Carvalho, 
Julisa C.L.Ribalta, Ismael D.C.G. Silva, Maria Gerbase-DeLima  
 
Resumo apresentado no congresso 190 Congresso de Imunogenética e Conferência de 
Histocompatibilidade em Istambul/2005 e publicado no periódico Genes & Immunity, volume 6, 
suplemento 1, p. S37, em abril/2005. 
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Interaction of non-HLA polymorphisms in the cervical cancer 
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Resumo apresentado no XXI European Immunogenetics and Histocompatibility Conference e 
publicado no periódico Tissue Antigens, volume 69, número 5, p.449, em maio de 2007.  
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.4. Anexo #4 
 
 
Dados originais relativos ao estudo de polimorfismo gênico  
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Predicting tumor persistence after treatment in cervical cancer patients 
Gerdine Ferreira de Oliveira Sanson;Andrey Morgun;Valeska Guzman;Anatoliy 
Yambartsev;Amador Gonçalves-Primo;Sylvia M F Brenna;C R N Carvalho;J C L 
Ribalta;Ismael D C G Silva;Natalia Shulzhenko;Maria Gerbase de Lima;  
 
 
Resumo apresentado no Conferencia Internacional em Bioinformática e Biologia Computacional 
(ICOBICOBI) realizado em Angra dos Reis, Rio de Janeiro, em October 25 – 28, 2004 e publicado 
nos anais do congresso p-48. 
 
 
Predicting tumor persistence after treatment in cervical cancer patients 
 
Gerdine Ferreira de Oliveira Sanson;Andrey Morgun;Valeska Guzman;Anatoliy 
Yambartsev;Amador Gonçalves-Primo;Sylvia M F Brenna;C R N Carvalho;J C L 
Ribalta;Ismael D C G Silva;Natalia Shulzhenko;Maria Gerbase de Lima;  
 
Prediction of response to a treatment is a very important question that was successfully investigated 
using microarrays in many types of cancers. In the present study we determined the difference 
between expression profiles of uterine cervix cancer biopsies from patients with and without 
persistence of disease after treatment. We explored differences of gene expression patterns, on 
microarray chips containing 14,000 genes, in 34 tumor samples with 9 known cases of disease 
persistence after the treatment and 25 without persistence. RNA was isolated, amplified in two 
rounds, and samples without persistence were grouped in 12 pools, each pool comprising two 
samples. We have found a set of 1573 genes (p<0.002) with differential expression pattern between 
persistence (P) and non-persistence (NP) samples. However, groups P and NP were heterogeneous 
regarding disease stages and type of treatment. Therefore, in order to prevent from association with 
variables other than persistence, we obtained genes differentially expressed between the two disease 
stages and two types of treatment. Then genes common between the 1573 gene list and the latter 
two lists were taken out from the first one. Also we compared P and NP using only IIIb stage samples, 
where we found 319 genes. We observed 153 genes common in the P vs. NP comparisons of the 
entire sample set and of the IIIb stage samples which should be mostly specific for discrimination 
between persistence and non-persistence. Indeed, class prediction using these genes allowed a 
correct classification of about 90% of samples with permutation p value <0.05. Gene Ontology 
analysis showed that among persistence vs. non-persistence profile was .immune response. group of 
genes which is probably specific to altered response to virus in cervical cancer. However, other 
groups such as .cell cycle regulation. and .cell-cell signaling. represent generic characteristics of 
cancer process itself. We.ve found different expression profiles between samples from patients with 
and without persistence of tumor after treatment. These diverse genetic profiles may help not only for 
prediction of short-term outcome of cervical cancer treatment but also for better understanding 
molecular pathways of this disease and establishment of new targets for its treatment. 
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Dados originais relativos ao estudo de expressão gênica
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Tabela 1A – Número de cópias (valores não normalizados) de cDNA dos genes referência e alvos incluídos no estudo para cada 
amostra analisada 
 
PAPD5 e DHPS - valor de quantidade de cDNA do gene de referência obtido no PCR em tempo real;  
PAPD5' – valor obtido através da equação da reta;  Índice - valor utilizado para normalizar o gene alvo;  
CD28, ICOS, ICOSL, CD80, CD86, CTLA4 e GZMB - valor de quantidade de cDNA do gene alvo obtido no PCR em tempo real 
Amostras PAPD5 
 
DHPS 
 
PAPD5'= 
0,1676*(PAPD5)+331,85 
Índice= 
(PAPD5'+DHPS)/2 
CD28 
 
ICOS 
 
CD80 
 
CD86 
 
ICOSL 
 
CTLA4 
 
GZMB 
 
1A 217,883 
34,071 
 
368,367 
201,219 
 
7,344 
 
4,877 16,855 28,232 13,131 2,500 10,158 
2A 
3744,976 
 
630,477 
 
959,508 
 
794,992 
 
179,919 
 
312,977 173,478 230,177 125,041 3,035 2100,499 
3A 2061,380 
 
567,305 
 
677,337 
 
622,321 
 
60,542 
 
81,563 35,393 107,445 134,137 2,182 985,449 
4A 
11480,185 
 
1927,800 
 
2255,929 
 
2091,865 
 
854,533 
 
817,110 462,421 576,200 419,454 21,793 1012,334 
5A 
17859,460 
 
3648,141 
 
3325,095 
 
3486,618 
 
905,174 
 
593,877 189,044 743,884 1111,064 45,257 1637,990 
6A 
3531,800 
 
1203,578 
 
923,780 
 
1063,679 
 
243,989 
 
135,162 312,533 541,450 116,978 13,122 3814,562 
7A 
668,440 
 
812,512 
 
443,881 
 
628,196 
 
42,007 
 
16,540 89,839 110,490 70,830 1,308 153,278 
8A 26,120 
 
56,499 
 
336,228 
 
196,363 
 
5,756 
 
6,835 26,468 65,216 2,282 1,024 449,692 
9A 
40,289 
 
38,313 
 
338,602 
 
188,458 
 
3,050 
 
4,518 3,332 37,040 9,766 2,556 126,633 
10A 
12404,298 
 
2712,201 
 
2410,810 
 
2561,506 
 
543,500 
 
688,512 695,731 804,023 969,733 69,289 995,101 
11A 152,551 
 
30,244 
 
357,418 
 
193,831 
 
16,524 
 
5,944 1,263 16,187 4,414 2,001 78,676 
12A 4350,898 
 
851,174 
 
1061,060 
 
956,117 
 
135,096 
 
161,162 138,638 500,008 204,238 4,952 2088,995 
13A 
23838,550 
 
4128,311 
 
4327,191 
 
4227,751 
 
4996,732 
 
5398,237 1060,093 1389,002 2695,727 74,633 33072,895 
14A 
4972,000 
 
1205,080 
 
1165,157 
 
1185,119 
 
517,514 
 
735,073 465,999 1161,543 322,439 60,021 15499,065 
15A 16789,530 
 
2370,425 
 
3145,775 
 
2758,100 
 
245,371 
 
342,012 945,108 1856,408 244,846 30,784 18594,712 
16A 
5842,274 
 
2392,074 
 
1311,015 
 
1851,545 
 
689,890 
 
480,025 531,182 598,613 376,807 61,862 5998,792 
17A 
135,280 
 
117,282 
 
354,523 
 
235,902 
 
134,660 
 
38,796 12,848 7,580 289,187 1,092 7255,184 
18A 6598,101 
 
2476,880 
 
1437,692 
 
1957,286 
 
144,330 
 
177,660 550,068 924,708 217,927 29,498 956,323 
      
 
 
 
 
 
 
Tabela 1B – Valores (em UR – unidade relativa) normalizados de expressão dos genes alvos para cada amostra 
analisada 
 
 
 
Amostras CD28 (UR) ICOS (UR) CD80 (UR) CD86 (UR) ICOSL (UR) CTLA4 (UR) GZMB(UR) 
1A 0,036 0,024 0,084 0,140 0,065 0,012 0,050 
2A 0,226 0,394 0,218 0,290 0,157 0,004 2,642 
3A 0,097 0,131 0,057 0,173 0,216 0,004 1,584 
4A 0,409 0,391 0,221 0,275 0,201 0,010 0,484 
5A 0,260 0,170 0,054 0,213 0,319 0,013 0,470 
6A 0,229 0,127 0,294 0,509 0,110 0,043 3,586 
7A 0,067 0,026 0,143 0,176 0,113 0,021 0,244 
8A 0,029 0,035 0,135 0,332 0,012 0,007 2,290 
9A 0,016 0,024 0,018 0,197 0,052 0,005 0,672 
10A 0,212 0,269 0,272 0,314 0,379 0,001 0,388 
11A 0,085 0,031 0,007 0,084 0,023 0,010 0,406 
12A 0,141 0,169 0,145 0,523 0,214 0,005 2,185 
13A 1,182 1,277 0,251 0,329 0,638 0,018 7,823 
14A 0,437 0,620 0,393 0,980 0,272 0,051 13,078 
15A 0,089 0,124 0,343 0,673 0,089 0,011 6,742 
16A 0,373 0,259 0,287 0,323 0,204 0,033 3,240 
17A 0,571 0,164 0,054 0,032 1,226 0,005 30,755 
18A 0,074 0,091 0,281 0,472 0,111 0,015 0,489 
7.2.7. Anexo #7 
 
 
Características demográficas e evolução relativas ao estudo de expressão 
gênica
  
Tabela 2 -  Dados demográficos e evolução 
No Pré-tratamento Tratamento Evolução nos 6 meses pós-tratamento  
Amostras Raça Idade 
 
Diagnóstico 
histológico 
Radio (RT)/Quimio (QT) 
 
 Óbito 
dias pós-tratamento 
causa morte 
Tumor presente 
Dias pós- trat. 
Exame 
Tumor ausente 
Dias pós- trat. 
Exame 
1A Parda 67 CEC RT  Não  180 dias – exame especular 
2A Branca 48 CEC RT  Não  180 dias – exame especular 
3A Negra 51 CEC RT  Não  180 dias – exame especular 
4A Branca 36 CEC RT   Não  180 dias – exame especular 
5A Branca 55 CEC RT  Não  180 dias – exame especular 
6A Branca 59 CEC RT  Não  180 dias – exame especular 
7A Branca 72 CEC RT  Não  180 dias – exame especular 
8A Negra 57 CEC RT   Não  180 dias – exame especular 
9A Branca 51 CEC RT/QT  Não  180 dias – exame citologia 
10A Branca 38 CEC RT/QT  Não  
180 dias – exame especular,  
citologia e ressonância 
magnética 
11A Branca 57 ADENO RT 
  
Óbito 15 dias – metástase 
pulmonar 
Sim  
12A Branca 37 CEC RT  
Óbito 30 dias – mestástase 
pulmonar Sim  
13A Branca 55 CEC RT  
Não 60 dias – exame 
especular 
 
14A Branca 45 CEC RT  
Não 54 dias – exame 
especular  
15A Branca 58 CEC RT  
Não 180 dias – exame 
especular e citologia 
 
16A Branca 30 CEC RT  
Óbito 120 dias -  
Metastase hepática e 
tuberculose 
77 dias – exame 
especular e citologia 
 
17A Branca 58 CEC RT   Não 
30 dias – exame 
especular e citologia 
 
18A 
Branca 55 CEC RT/QT  Não 
30 dias – exame 
especular, citologia 
e ressonãncia 
magnética 
 
Todas as pacientes completaram o tratamento em até 3 meses. RT para todas as pacientes foi na pelve (4500 cGy), paramétrio e braquiterapia. QT foi cisplatina (60mg/m2). 
Nenhuma paciente recebeu outro tratamento adicional a RT e/ou QT. 
CEC – Diagnóstico histológico de carcionoma espinocelular e ADENO - Diagnóstico histológico de adenocarcinoma 
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ABSTRACT 
The aims of the study were: 1) to search association between 
polymorphisms in CD28, CTLA4, ICOS, PDCD1, FAS, TNFA, IL6, IFNG, 
TGFB1 and IL10 genes and cervical cancer using both single-locus and 
multi-locus analysis approaches; 2) to assess, in invasive cervical 
carcinoma, expression levels of CD28, CTLA4, ICOS, ICOSL, CD80, 
CD86, GZMB (granzima B) genes and seek correlation to response to 
treatment. Material & Methods: 1) PCR-RFLP was applied to detect the 
CD28 intron 3 (+17 T>C), CTLA4 promoter (-319 C>T), CTLA4 exon 1 
(+49 A>G), ICOS 3’UTR (+1564 T>C), PDCD1 exon 5 (+7785 C>T) and 
FAS promoter (-670 G>A) SNPs. TNFA promoter (-308 G>A), IL6 promoter 
(-174 G>C), IFNG intron 1 (+874 A>T), TGFB1 codon 10 (+869 T>C), 
codon 25  (+915 G>C) and IL10 promoter (-1082 A>G), (-819 C>T), (-592 
C>A) SNPs were determined by PCR-SSP. A new statistical approach was 
used to indentify isolated polymorphism and/or two- and three-
polymorphism combinations associated with the disease in three case-
control groups; 2) Expression levels of CD28, CTLA4, ICOS, ICOSL, 
CD80, CD86 and granzyme B genes were assessed by real-time RT-PCR 
in pre-treatment tumor fragments. The treatment consisted of radiotherapy 
only or radiotherapy plus chemotherapy. During the six-month follow-up 
after treatment, eight patients presented tumor (poor outcome group) and 
ten survived free-of tumor (good outcome group). Results: 1) No 
significant association was observed with any individual SNP. The multi-
locus analysis revealed higher frequencies, in cancer patients, of three 
three-genotype combinations (CD28+17(TT)/IFNG+874(AA)/TNFA-
308(GG), CD28+17(TT)/IFNG(AA)/PDCD1+7785(CT), and CD28 
+17(TT)/IFNG+874(AA)/ICOS+1564(TT) (p<0.01, Monte Carlo simulation). 
However, the third (TNFA, ICOS, or PDCD1) locus contribution was not 
confirmed (p=0.10, Monte Carlo Simulation). We analyzed frequencies of 
CD28(TT)/IFNG(AA) genotype combination in the three groups together 
and observed its increase in patients (OR = 2,07, p=0,0011 by Fisher’s 
exact test); 2) The only gene whose expression was different between poor 
and good outcome groups was granzyme B, being the expression levels 
higher in patients with poor outcome (medians of 4.991 vs 0.578 relative 
units, p=0.034). Coclusions: 1) Our results showed an epistatic effect 
between CD28 and IFNG genes in susceptibility to cervical cancer, a 
finding that might be relevant for a better understanding of the disease 
pathogenesis. In addition, the novel analytical approach herein proposed 
might be useful for increasing the statistical power of future genome-wide 
multi-locus studies. 2) Our results suggest that high pre-treatment 
granzyme B mRNA level is a potential marker for stage IIIB cervical cancer 
poor response to therapy. Further evaluation, in adequately powered 
prospective studies is warranted to confirm the data and to translate this 
observation to the clinical setting. 
 
 
